
First-Line Ivonescimab Plus Chemo Improves PFS in Advanced Squamous NSCLC
Treatment with the PD-1– and VEGF-directed bispecific antibody ivonescimab (SMT112) in combination with chemotherapy resulted in a statistically significant and clinically meaningful progression-free survival (PFS) improvement vs tislelizumab (Tevimbra) in …